UK-2A, B, C and D, Novel Antifungal Antibiotics from Streptomyces sp. 517-02. II. Structural Elucidation.

UK-2A, B, C and D, Novel Antifungal Antibiotics from Streptomyces sp. 517-02. II. Structural Elucidation. UK-2A, B, C and D, Novel Antifungal Antibiotics from Streptomyces sp. 517-02. I. Fermentation, Isolation, and Biological Properties. UK-2A, B, C and D, Novel Antifungal Antibiotics from Streptomyces sp. 517-02. I. Fermentation, Isolation, and Biological Properties. UK-3A, a Novel Antifungal Antibiotic from Streptomyces sp. 517-02: Fermentation, Isolation, Structural Elucidation and Biological Properties. UK-3A, a Novel Antifungal Antibiotic from Streptomyces sp. 517-02: Fermentation, Isolation, Structural Elucidation and Biological Properties. Structure–activity relationship studies on UK-2A, a novel antifungal antibiotic from Streptomyces sp. 517-02. Part 5: Roles of the 9-membered dilactone-ring moiety in respiratory inhibition UK-2A, B, C and D, Novel Antifungal Antibiotics from Streptomyces sp. 517-02. III. Absolute Configuration of an Antifungal Antibiotic, UK-2A, and Consideration of Its Conformation. Semi-synthesis and biological evaluation of analogues of UK-2A, a novel antifungal antibiotic from Streptomyces sp. 517-02 UK-1, a Novel Cytotoxic Metabolite from Strcptomyces sp. 517-02. III. Antibacterial Action of Demethyl UK-1. The Mode of Action of UK-2A and UK-3A, Novel Antifungal Antibiotics from Streptomyces sp. 517-02.